Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

127results about How to "Useful in preparation" patented technology

Three-dimensional Printing System and Equipment Assembly

ActiveUS20140065194A1Minimal product lossHigh product reproducibilityManufacturing platforms/substratesLayered productsManufacturing engineering3 dimensional printing
A three-dimensional printing system and equipment assembly for the manufacture of three-dimensionally printed articles is provided. The equipment assembly includes a three-dimensional printing build system, an optional liquid removal system and an optional harvester system. The build system includes a conveyor, plural build modules and at least one build station having a powder-layering system and a printing system. The equipment assembly can be used to manufacture pharmaceutical, medical, and non-pharmaceutical / non-medical objects. It can be used to prepare single or multiple articles.
Owner:APRECIA PHARMA LLC

Malleable multi-component implants and materials therefor

Described are implantable, malleable medical materials comprising mineral particles, insoluble collagen fibers, and a gel-forming polysaccharide component and / or another added gel-former. The malleable medical materials can be used treat bone or other tissue defects in patients, including in conjunction with biologically active factors such as osteogenic proteins. Also described are methods and materials that can be used to prepare the malleable medical materials.
Owner:WARSAW ORTHOPEDIC INC

Biocompatible macromers

A new oligomer based on alternating fumaric acid and poly(ethylene glycol) (PEG) units is provided. The oligo(PEG fumarate) (OPF) may be functionalized by modification with a biocompatible organic group. Further, the OPF may be cross-linked using radical polymerization in the presence of either a chemical or photo initiator. A cross-linked OPF gel has a swelling behavior that is tunable dependent on the molecular weight of PEG. A cross-linkable PEG macromer, as exemplified by oligo(PEG fumarate), has unsaturated double bonds, for example in the fumaryl groups, along its macromolecular chain that allows for the preparation of hydrogels with tailored structure and properties.
Owner:RICE UNIV

Three-dimensional Printing System and Equipment Assembly

A three-dimensional printing system and equipment assembly for the manufacture of three-dimensionally printed articles is provided. The equipment assembly includes a three-dimensional printing build system, an optional liquid removal system and an optional harvester system. The build system includes a conveyor, plural build modules and at least one build station having a powder-layering system and a printing system. The equipment assembly can be used to manufacture pharmaceutical, medical, and non-pharmaceutical / non-medical objects. It can be used to prepare single or multiple articles.
Owner:APRECIA PHARMA LLC

Universal support for the synthesis of oligonucleotides

A universal polymer support containing an organic aliphatic molecule of structure having at least a pair of cis-hydroxyl groups where one of the hydroxyl groups is attached to the polymer support through a covalent linkage and the other hydroxyl group is protected by an acid labile group.
Owner:COUNCIL OF SCI & IND RES +1

5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family

InactiveUS20080125432A1Useful in preparationBiocideSenses disorderIonIon Channel Interactions
The present invention relates to compounds that interact with ion channels. In particular, the invention relates to compounds having the structural Formula having the structural Formula I, II, III or IV, stereoisomers, tautomers, racemics, prodrugs, metabolites thereof, or a pharmaceutically acceptable salt and / or solvate thereof,wherein X, Y1, Y2, R1, n, R3, R8, R9, R10, L1, L2, Ar1 and Ar2 are defined in claim 1. The invention also relates to methods for preparing said compounds, to pharmaceutical compositions comprising said compounds, and to the use of said compounds in methods for treatment of the human and animal body.
Owner:DEVGEN NV

Cold curable isocyanate adhesives with reduced foaming

InactiveUS20050010013A1ViscosityLow composition viscosityPolyureas/polyurethane adhesivesAdhesiveComposite lumber
Moisture activated polyisocyanate adhesives comprising isocyanate terminated prepolymers that provide rapid curing at relatively low temperatures. The adhesives have reduced tendency toward foaming and exhibit excellent gap filling characteristics. The adhesive compositions are suitable for use as wood adhesives, and are especially suitable for engineered composite lumber applications.
Owner:HUNTSMAN INT LLC

Gas storage materials and devices

The invention provides a porous metal-organic framework that can be used to store gases, such as hydrogen. Also provided is metal-organic framework comprising bifunctional metallic bridging groups and organic nodes having three or more points of connection, wherein the framework has one or more cavities suitable for containing one or more storage gas molecules. The invention further provides a metal-organic framework comprising organic functional groups directed into the one or more cavities that are capable of reacting with a storage gas.
Owner:UNIV OF IOWA RES FOUND

Glycolipids derivatives, process for production of the same, intermediates for synthesis thereof, and process for production of the intermediates

ActiveUS20060074235A1Good quality improved in physical propertyUseful in preparationNervous disorderAntipyreticArylCarbon chain
Novel glycolipid derivatives, where the substituent of the sphingosine base part is a short carbon chain alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted aryl group or substituted or unsubstituted aralkyl group and efficient synthetic methods for practical mass production of the same and intermediates useful for the synthesis of these compounds. Glycolipids having the formula (I): where R3 indicates a substituted or unsubstituted C1 to C7 linear alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted aryl group, or substituted or unsubstituted aralkyl group and R8 indicates a substituted or unsubstituted C1 to C35 alkyl group, substituted or unsubstituted aryl group or substituted or unsubstituted aralkyl group are chemically synthesized.
Owner:JAPAN REPRESENTED BY PRESIDENT OF NAT CENT OF NEUROLOGY & PSYCHIATRY KODAIRA

P13 antigens from Borrelia

The invention relates to an isolated nucleic acid fragment whichencodes a polypeptide fragment which exhibits a substantial immunological reactivity with a rabbit polyclonal antibody raised against a polypeptide having an apparent molecular weight of 13 kDa as determined by SDS-PAGE followed by visualization, said polypeptide being derived from Borrelia burgdorferi B313 and being encoded by the nucleotide sequence of SEQ ID NO: 18, said rabbit polyclonal antibody exhibiting substantially no immunological reactivity with proteins from at least 95% of spirochaetes randomly selected from the group consisting of Borrelia hermsii, Borrelia crocidurae, Borrelia anserina, and Borrelia hispanica, and / orhybridises readily under highly stringent hybridization conditions with a DNA fragment having a nucleotide sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 20, and SEQ ID NO: 22, or with a DNA fragment complementary thereto, but exhibits no substantial hybridization when the hybridization conditions are highly stringent with genomic DNA from at least 95% of spirochaetes randomly selected from the group consisting of Borrelia hermsii, Borrelia crocidurae, Borrelia anserina, and Borrelia hispanica.Furthermore, the invention relates to polypeptide fragments, vectors, transformed cells and cell lines, a method of preparing a polypeptide fragment and, vaccines as well as diagnostic compositions and kits.
Owner:SYMBICOM

3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists

The invention provides 3-carboxypropyl-aminotetralin compounds of formula (I):wherein R1, R2, R3, R4, R5, and R6 are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
Owner:THERAVANCE BIOPHARMA R&D IP LLC

Ink jet recording medium comprising amine-treated silica

This invention pertains to an ink jet recording medium comprises a flexible substrate and a coating composition coated on at least one surface of the substrate, wherein the coating composition comprises the product formed from the contact between fumed silica particles and at least one aminoorganosiloxane. The invention also pertains to a method for the preparation of such an ink jet recording medium and to methods for the preparation of a coating composition and a dispersion useful in the preparation of such an ink jet recording medium.
Owner:CABOT CORP

Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

InactiveUS20090062335A1Reduce exerciseUseful in preparationBiocideNervous disorderOpioid receptorMu-opioid receptor activity
The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I):wherein R1, R2, R3, and a are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
Owner:THERAVANCE BIOPHARMA R&D IP LLC

8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists

InactiveUS20090062333A1Reduce exerciseUseful in preparationBiocideNervous disorderOpioid receptorMu-opioid receptor activity
The invention provides 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds of formula (I):wherein R2, R7, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
Owner:THERAVANCE BIOPHARMA R&D IP LLC

Otft using paper as substrate and silk protein as insulating material and method for manufacturing the same

An organic thin film transistor (OTFT) using paper as a substrate and silk protein as an insulating material and methods for manufacturing the same are disclosed. The OTFT of the present invention comprises: a paper substrate; a gate disposed on the paper substrate; a gate insulating layer containing silk protein, which is disposed on the paper substrate and covers the gate; an organic semiconductor layer; and a source and a drain, wherein the organic semiconductor layer, the source and the drain are disposed over the gate insulating layer.
Owner:NATIONAL TSING HUA UNIVERSITY

Derivatives of 4-(2-amino -1-hydroxyethyl)phenol as agonists of the Beta2 adrenergic receptor

A compound of formula (I) or a pharmaceutically-acceptable salt, solvate or stereoisomer thereof wherein R1 is a group chosen from —CH2OH and —NHC(O)H; R2 is a hydrogen atom or R1 together with R2 form the group —NH—C(O)—CH═CH—, wherein the nitrogen atom is bound to the carbon atom in the phenyl ring holding R1 and the carbon atom is bound to the carbon atom in the phenyl ring holding R2; R3 is chosen from a hydrogen atom, a halogen atom and groups chosen from —SO—R5, —SO2—R5, —NH—CO—NH2, —CO—NH2, hydantoino, C1-4alkyl, C1-4alkoxy and —SO2NR5R6; R4 is chosen from a hydrogen atom, a halogen atom and a C1-4 alkyl group; R5 is chosen from a C1-4 alkyl group and a C3-8 cycloalkyl group; R6 is independently chosen from a hydrogen atom and a C1-4 alkyl group; n, p and q are independently 0, 1, 2, 3 or 4; m and s are independently 0, 1, 2 or 3; and r is 0, 1 or 2 with the provisos that at least one of m and r is not 0, the sum n+m+p+q+r+s is 7, 8, 9, 10, 11, 12 or 13, and the sum q+r+s is 2, 3, 4, 5 or 6.
Owner:ALMIRALL

Method for preparing biomass-based polymer emulsion

A method for preparing biomass-based polymer emulsion. The method includes: 1) preparing cardanol-based polymerizable emulsifier; 2) preparing castor oil-based polyurethane prepolymer; and 3) preparing biomass-based polymer emulsion.
Owner:ZHONGYING CHANGJIANG INTERNATIONAL NEW ENERGY INVESTMENT CO LTD

Use of riluzole for the treatment of multiple sclerosis

Methods for the treatment of multiple sclerosis are disclosed comprising administering 6-(triflouromethoxy)-2-benzothiazolamine or a salt thereof.
Owner:VER VOOR CHRISTELIJK WETENSHAPPELIKJK ONDERWIJS

High-strength cross-linked polymer photonic crystal film

The present invention provides a method for preparing high-strength cross-linked polymer photonic crystal film by core-shell polymer microspheres via evaporation-induced self assembly. Monodispersed core-shell polymer microspheres are fabricated by emulsifier-free emulsion polymerization, and then the microspheres emulsion is coated onto suitable substrates. Finally, polymer photonic crystal film with long-range ordered is constructed via self assembly. Self-cross-linking between the two units improves the strength of the polymer photonic crystal film, therefore the preparation of large size industrial-grade photonic crystal film is practicable which extends its application on the field of dyeing.
Owner:XIAMEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products